[HTML][HTML] Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on�…

JM Jones�- MMWR. Morbidity and mortality weekly report, 2023 - cdc.gov
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among US infants.
In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting�…

[HTML][HTML] Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First�…

HL Moline�- MMWR. Morbidity and mortality weekly report, 2024 - cdc.gov
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the
United States. In August 2023, CDC's Advisory Committee on Immunization Practices�…

[HTML][HTML] Single-dose nirsevimab for prevention of RSV in preterm infants

MP Griffin, Y Yuan, T Takas…�- …�England Journal of�…, 2020 - Mass Medical Soc
Background Respiratory syncytial virus (RSV) is the most common cause of lower
respiratory tract infection in infants, and a need exists for prevention of RSV in healthy�…

Nirsevimab for prevention of RSV in healthy late-preterm and term infants

LL Hammitt, R Dagan, Y Yuan…�- …�England Journal of�…, 2022 - Mass Medical Soc
Background Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract
infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV�…

[HTML][HTML] Nirsevimab for prevention of hospitalizations due to RSV in infants

SB Drysdale, K Cathie, F Flamein, M Knuf…�- …�England Journal of�…, 2023 - Mass Medical Soc
Background The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab
on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract�…

Nirsevimab for prevention of RSV in term and late-preterm infants

WJ Muller, SA Madhi, B Seoane Nunez…�- …�England Journal of�…, 2023 - Mass Medical Soc
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced�…

Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model

A Kieffer, M Beuvelet, A Sardesai…�- The Journal of�…, 2022 - academic.oup.com
Background Respiratory syncytial virus (RSV) is associated with substantial morbidity in the
United States, especially among infants. Nirsevimab, an investigational long-acting�…

Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity

J Domachowske, SA Madhi, EAF Sim�es…�- …�England Journal of�…, 2022 - Mass Medical Soc
Nirsevimab for Prevention of RSV Nirsevimab is a monoclonal antibody targeting respiratory
syncytial virus. In this trial, the safety of nirsevimab was assessed in infants eligible to�…

Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: a systematic review and network meta-analysis

M Sun, H Lai, F Na, S Li, X Qiu, J Tian…�- JAMA Network�…, 2023 - jamanetwork.com
Importance Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory
infection in children younger than 5 years; effective prevention strategies are urgently�…

Nirsevimab and hospitalization for RSV bronchiolitis

Z Assad, AS Romain, C Aupiais, M Shum…�- …�England Journal of�…, 2024 - Mass Medical Soc
Background Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis, resulting
in 3 million hospitalizations each year worldwide. Nirsevimab is a monoclonal antibody�…